Table 2 Characteristics and outcomes of infection episodes.
From: Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Characteristic | Detail (n = 111) |
|---|---|
Treatment course | |
BsAb cycles at time of infection (median, IQR) | 2 (1–7) |
Cumulative prednisone-equivalent dose, 30 days (mg; median, IQR) | 266.7 (106.7–266.7) |
Lowest neutrophil level, 14 days prior (x109/L; median, IQR) | 1.8 (1.1–2.3) |
Lowest lymphocyte count, 14 days prior (x109/L; median, IQR) | 0.3 (0.1–0.7) |
Prophylaxis (n, %) | |
Antiviral | Valaciclovir: 104 (94) Valganciclovir: 3 (3) Famciclovir: 3 (3) None: 1 (1) |
Antifungal | Fluconazole: 9 (8) Mould-active antifungal: 29 (26)  Posaconazole: 24 (22)  Voriconazole: 5 (5) None: 73 (66) |
 P. jirovecii prophylaxis | Trimethoprim/Sulfamethoxazole: 104 (94) Dapsone: 5 (5) None: 2 (2) |
Infection details | |
Number of patients (n, %) | 35 (90) |
Grade of infection | 1: 37 (33) 2: 50 (45) 3: 22 (20) 4: 0 (0) 5: 2 (2) |
Infection category! | MDI: 33 (30) CDI: 43 (39) FUF: 35 (32) |
Site of infection | Respiratory: 46 (41) Urinary: 4 (4) Bloodstream: 6 (5) Skin and soft tissue: 4 (4) Gastrointestinal tract: 8 (7) Ear nose and throat: 6 (5) Genital: 2 (2) CRS: 31 (28) Unknown: 4 (4) |
Pathogen details (n, %) | |
Pathogens isolateda | Bacterial: 15 (39)  Gram Negative: 12 (32)1  Gram Positive: 3 (8)2 Viral: 22 (58) Respiratory viruses: 15 (39)3 Reactivated viruses: 7 (18)4 AFB: 1 (3)5 |
Treatment and outcomes | |
Total antibiotic duration (days; median, IQR)  IV  PO | 5 (3–9) 3 (3–4) 5 (5–10) |
Hospital admission (n, %) | 63 (57) |
Outcome at 30 days (n, %) | Survival: 108 (97) Death: 3 (3)6 |
